ClinicalTrials.gg
RecruitingNCT07038408LNBUpdated Apr 30, 2026

Leave Nothing Behind Study Which Compares DCB With Bail Out BRS Versus BRS Strategy Alone

An interventional study of Angioplasty with DCB (bail-out BRS) and Angioplasty with BRS in Drug Coated Balloon, Bioresorbable Scaffold and Percutaneous Coronary Intervention (PCI), sponsored by Ceric Sàrl. Recruiting at 1 site in Estonia. Open to participants aged 18 Years to 68 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Ceric Sàrl · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,256
Allocation
Randomized
Ages
18 Years to 68 Years
Sex
All
01

Study summary

The goal of this study is to investigate the equivalence in early and long-term efficacy between the two "Leave nothing behind strategies" (Drug-Coated Baloon [DCB] strategy with bail-out BioResorbable Scaffold [BRS] versus BRS strategy) of de-novo native coronary artery lesions in a relatively young Percutaneous Coronary Intervention (PCI) population, to be more specific, Patients with Chronic Coronary Syndromes (CCS) and Acute Coronary Syndrome (ACS) (Non-ST-segment Elevation Myocardial Infarction [NSTEMI] and Unstable angina) between 18-68 years of age scheduled for PCI. The main questions aim to answer are:

DCB strategy with bail-out BRS implantation has equivalent clinical outcomes at 12 months compared to BRS strategy? DCB strategy with bail-out BRS implantation has noninferior angiographic in-segment net gain at 13 months compared to BRS strategy? DCB strategy with bail-out BRS implantation has equivalent clinical outcomes at 60 months compared to BRS strategy?

Participants will be followed at:

  1. st FU visit - 1 month (in hospital)
  2. nd FU visit - 6 months (telephone)
  3. rd FU visit - 365 days±15 days (telephone) - 1Y Primary efficacy endpoint
  4. th FU visit - 395 days±15 days (in hospital) co-primary efficacy endpoint for the angiographic substudy
  5. th FU visit - 730 days±30 days (telephone call) - 2Y
  6. th FU visit - 1095 days±30 days (telephone call) - 3Y
  7. th FU visit - 1460 days±30 days (telephone call) - 4Y
  8. th FU visit- 1825 days±30 days (telephone call) - 5Y
Read the detailed description

The Leave Nothing Behind Study is an is an investigator-initiated trial. The Primary efficacy endpoint is target-vessel failure (TVF), defined as the composite of cardiovascular death, target-vessel myocardial infarction or ischemia-driven target-vessel revascularization (TVR) at 12 months.

Co-primary efficacy endpoint (angiographic substudy) is the in-segment net gain at 13 months.

Investigators aim to enroll 2256 patients in the main study and 196 patients in the angiographic substudy.

02

Conditions studied

  • Drug Coated Balloon
  • Bioresorbable Scaffold
  • Percutaneous Coronary Intervention (PCI)
  • Acute Coronary Syndrome (ACS)

Keywords

  • MULTI-CENTER
  • OPEN-LABEL
  • PROSPECTIVE
  • RANDOMIZED STUDY
  • LONG-TERM EFFICACY OF DCB TREATMENT WITH BAIL-OUT BRS
  • BRS TREATMENT
  • DE-NOVO NATIVE CORONARY ARTERY LESIONS
  • YOUNG PCI POPULATION
03

In context

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

This study's planned enrollment of 2,256 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.

Browse Acute Coronary Syndrome studies →

Lead sponsor

Ceric Sàrl is the lead sponsor of 17 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 68 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥ 18 years ≤ 68 years
  • Single vessel or multivessel disease with low to moderate complex de-novo native coronary artery lesions up to 30 mm length and reference vessel diameter 2.75-4.0 mm
  • Maximum of 3 target lesions
  • Maximal cumulative lesion length of all treated lesions 80 mm
  • Signed for participation in the study

Exclusion criteria

Exclusion Criteria:

  • ST-segment Elevation Myocardial Infarction (STEMI) treatment at index or in the previous 48 hours
  • Severe calcified lesions
  • Bifurcations lesions with planned 2 device strategy
  • Left-Main (LM) disease ≥ 50% diameter stenosis
  • More than 3 target lesions
  • Renal insufficiency with (GFR) \< 45 ml/min
  • less than 1 year
  • Known or allergy to aspirin or P2Y12 receptor inhibitors
  • Incapable of providing written
  • Pregnant or breastfeeding women
  • Under judicial protection, tutorship, or curatorship
  • Participation in another trial
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,256 participants (estimated)

Study arms

  • Experimental
    DCB treatment (Mozec SEB)

    Mozec SEB is used during the angioplasty (V2) for patients randomized in the DCB arm with bail-out BRS. If the operator considers the results as insufficient, the MeRes100 is also used in the patient.

    Procedure: Angioplasty with DCB (bail-out BRS)

  • Active comparator
    BRS treatment (MeRes100)

    MeRes100 is used during the angioplasty (V2) for patients randomized in the BRS arm.

    Procedure: Angioplasty with DCB (bail-out BRS) · Procedure: Angioplasty with BRS

Interventions

  • ProcedureAngioplasty with DCB (bail-out BRS)

    Angioplasty starts with lesion preparation in both arms with a PTCA balloon catheter. The lesion is treated with the Mozec SEB through femoral or brachial artery. The DCB should be delivered to the target lesion within 120 seconds of insertion into the guide catheter. Under fluoroscopic visualization, the DCB is inflated at least 30 seconds (single inflation). If the results are insufficient, multiple inflation is permitted. If despite appropriate delivery and inflation of the DCB, the results remain insufficient bail-out BRS should be performed. Bail-out BRS is performed through femoral or brachial artery. After correct positioning, the BRS is deployed slowly, i.e. 10 seconds/atm up to 4 atm, then 5 seconds/atm up to nominal pressure or higher until desired expansion is obtained. After desired expansion obtained, pressure is maintained for 30 seconds before balloon deflation. After BRS implantation, Optical Coherence Tomography (OCT) is performed, if available.

    Also known as: DCB arm with bail-out BRS

  • ProcedureAngioplasty with BRS

    Bail-out BRS is performed through femoral or brachial artery. BRS implantation is guided by OCT, if available. After correct positioning, the BRS is deployed slowly, i.e. 10 seconds/atm up to 4 atm, then 5 seconds/atm up to nominal pressure or higher until desired expansion is obtained. After desired expansion obtained, pressure is maintained for 30 seconds before balloon deflation. After BRS implantation, OCT is performed, if available.

    Also known as: BRS arm

06

What researchers measure

Primary outcomes

  1. Target-vessel Failure (TVF)

    Target vessel failiure is defined as the composite of cardiovascular death, target-vessel myocardial infarction or ischemia-driven target-vessel revascularization

    Time frame: From enrollment to the end of treatment at 12 months

Secondary outcomes

  1. Target-Vessel Failure (TVF) at 2, 3, 4 and 5 years.

    Target vessel failiure is defined as the composite of cardiovascular death, target-vessel myocardial infarction or ischemia-driven target-vessel revascularization

    Time frame: From enrollment to the end of treatment at every year from 2 years until 5 years follow-up

  2. Target-Lesion Failure (TLF)

    Target Lesion Failure is is defined as the composite of cardiac death, target vessel-related myocardial infarction (Q wave and non-Q wave) and ischemia-driven target lesion revascularization

    Time frame: From enrollment to the end of treatment every year until end of 5 years

  3. (Bleeding Academic Research Consortium) BARC 2, 3 or 5 bleedings

    BARC definitions Type 2: any overt, actionable sign of hemorrhage that does not fit the criteria for type 3, type 4, or type 5 but does meet at least one of the following criteria: requiring nonsurgical, medical intervention by a health care professional; leading to hospitalization or increased level of care; or prompting evaluation. Type 3a: overt bleeding plus a hemoglobin drop of 3 to 5 g/dL\* ; any transfusion with overt bleeding. Type 3b: overt bleeding plus a hemoglobin drop of 5 g/dL ; cardiac tamponade; bleeding requiring surgical intervention for control ; bleeding requiring intravenous vasoactive agens. Type 3c: intracranial hemorrhage

    Time frame: From enrollment to the end of treatment every year until end of 5 years

  4. Net Adverse Clinical Event (NACE)

    NACE defined as all-cause death, myocardial infarction, all-stroke, ischemia driven TVR or BARC 3 or 5 bleeding

    Time frame: From enrollment to the end of treatment every year until end of 5 years

Other outcomes

  1. Acute Gain

    Acute gain (in-lesion and in-segment)

    Time frame: From enrollment to the end of treatment at 13 months

  2. Late Loss

    Late loss (in-lesion and in-segment)

    Time frame: From enrollment to the end of treatment at 13 months

  3. In-segment Late Lumen Loss (LLL)

    In segment LLL in vessels with RVD \< 3.0 mm and ≥ 3.0 mm

    Time frame: From enrollment to the end of treatment at 13 months

07

Study locations

1 of 1 sites recruiting
  • Põhja-Eesti Regionaalhaigla
    Tallinn, 13419, Estonia
    Recruiting
    • Peep Laanmets · Contact
08

References and documents

Publications

  • Verma PK, Sroa S, Koushal P. A real-world experience with a thin-strut bioresorbable vascular scaffold system: a single-centre study. AsiaIntervention. 2025 Mar 20;11(1):26-34. doi: 10.4244/AIJ-D-24-00033. eCollection 2025 Mar. PubMed 40114731 ↗
  • Abizaid A, Kedev S, Ali RBM, Santoso T, Cequier A, van Geuns RVG, Chevalier B, Hellig F, Costa R, Onuma Y, Costa JR Jr, Serruys P, Bangalore S. Imaging and 2-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold: The MeRes-1 extend trial. Catheter Cardiovasc Interv. 2021 Nov 15;98(6):1102-1110. doi: 10.1002/ccd.29396. Epub 2020 Dec 2. PubMed 33269506 ↗
  • Seth A, Onuma Y, Chandra P, Bahl VK, Manjunath CN, Mahajan AU, Kumar V, Goel PK, Wander GS, Kaul U, Ajit Kumar VK, Abizaid A, Serruys PW. Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial. EuroIntervention. 2019 Sep 20;15(7):607-614. doi: 10.4244/EIJ-D-19-00324. PubMed 31147308 ↗
  • Premchand Jain RK, Parikh K, Sethuraman S, Sharma K, Roy S, Vithala SR, Gollamandala KR, Packirisamy G, Mantravadi SS, Roleder T. Safety and Performance of the MOZEC Sirolimus-Eluting Coronary Balloon in the Treatment of Stenotic Coronary Artery Lesions: A Real-World, Multicenter, Post-Marketing Surveillance Study. Cardiol Res. 2025 Apr;16(2):130-139. doi: 10.14740/cr2026. Epub 2025 Feb 28. PubMed 40051667 ↗
  • Capodanno D, Angiolillo DJ. Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions. JACC Cardiovasc Interv. 2017 Mar 13;10(5):425-437. doi: 10.1016/j.jcin.2016.12.279. PubMed 28279311 ↗
  • Tamburino C, Latib A, van Geuns RJ, Sabate M, Mehilli J, Gori T, Achenbach S, Alvarez MP, Nef H, Lesiak M, Di Mario C, Colombo A, Naber CK, Caramanno G, Capranzano P, Brugaletta S, Geraci S, Araszkiewicz A, Mattesini A, Pyxaras SA, Rzeszutko L, Depukat R, Diletti R, Boone E, Capodanno D, Dudek D. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention. 2015 May;11(1):45-52. doi: 10.4244/EIJY15M01_05. PubMed 25599676 ↗
  • Vanoverbeke L, Bennett J. Drug-eluting resorbable coronary scaffolds: a review of recent advances. Expert Opin Drug Deliv. 2025 Jul;22(7):919-933. doi: 10.1080/17425247.2025.2495043. Epub 2025 Apr 20. PubMed 40238640 ↗
  • Power DA, Camaj A, Kereiakes DJ, Ellis SG, Gao R, Kimura T, Ali ZA, Stockelman KA, Dressler O, Onuma Y, Serruys PW, Stone GW; ABSORB Investigators. Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold: Final Report From the ABSORB Clinical Trial Program. JACC Cardiovasc Interv. 2025 Jan 13;18(1):1-11. doi: 10.1016/j.jcin.2024.08.050. PubMed 39814482 ↗
  • Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, Alfonso F, Latib A, Ong PJ, Rissanen TT, Saucedo J, Scheller B, Kleber FX; International DCB Consensus Group. Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402. doi: 10.1016/j.jcin.2020.02.043. Epub 2020 May 27. PubMed 32473887 ↗
  • Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013 Jan 17;368(3):254-65. doi: 10.1056/NEJMra1210816. No abstract available. PubMed 23323902 ↗
  • Zhang YJ, Bourantas CV, Muramatsu T, Iqbal J, Farooq V, Diletti R, Campos CA, Onuma Y, Garcia-Garcia HM, Serruys PW. Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial. EuroIntervention. 2014 Oct;10(6):672-80. doi: 10.4244/EIJV10I6A118. PubMed 24472767 ↗
  • Asano T, Serruys PW, Collet C, Miyazaki Y, Takahashi K, Chichareon P, Katagiri Y, Modolo R, Tenekecioglu E, Morel MA, Garg S, Wykrzykowska J, Piek JJ, Sabate M, Morice MC, Chevalier B, Windecker S, Onuma Y. Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. Eur Heart J. 2018 Sep 21;39(36):3381-3389. doi: 10.1093/eurheartj/ehy436. PubMed 30124834 ↗
  • Madhavan MV, Kirtane AJ, Redfors B, Genereux P, Ben-Yehuda O, Palmerini T, Benedetto U, Biondi-Zoccai G, Smits PC, von Birgelen C, Mehran R, McAndrew T, Serruys PW, Leon MB, Pocock SJ, Stone GW. Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2020 Feb 18;75(6):590-604. doi: 10.1016/j.jacc.2019.11.058. PubMed 32057373 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2028, 31 months after the start.

Of 228 interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 46. This study's planned 31 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 26, 2025
StartActual
Apr 24, 2026
Primary completionEst.
Nov 30, 2028
CompletionEst.
Mar 2032
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07038408
Lead sponsor
Ceric Sàrl
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Apr 24, 2026
Primary completion
Nov 30, 2028 (estimated)
Completion
Mar 2032 (estimated)
Last update
Apr 30, 2026

Study contacts

DAVIDE CAPODANNO, Professor
Contact
dcapodanno@unict.it
+39-3393238566

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion